Search

Ipsen SA.

Geschlossen

BrancheFinanzen

121.3 2.1

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

118.5

Max

121.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

220M

334M

Verkäufe

-2.9M

1.8B

KGV

Branchendurchschnitt

21.173

27.91

Dividendenrendite

1.22

Gewinnspanne

18.354

Angestellte

5,358

EBITDA

-73M

637M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+20.42% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.22%

4.01%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

111M

9.4B

Vorheriger Eröffnungskurs

119.2

Vorheriger Schlusskurs

121.3

Nachrichtenstimmung

By Acuity

34%

66%

113 / 528 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Ipsen SA. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Dez. 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Ipsen SA. Prognose

Kursziel

By TipRanks

20.42% Vorteil

12-Monats-Prognose

Durchschnitt 136.2 EUR  20.42%

Hoch 148 EUR

Tief 120 EUR

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ipsen SA. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

3

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

99.85 / 104Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

113 / 528 Ranking in Finanzen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat